Table 3.

Characteristics of study groups and outcomes for RE-LY Trial

Characteristics of study groups and outcomes for RE-LY Trial

BID indicates twice daily; D, dabigatran etexilate; RR, relative risk; CI, confidence interval; TIA, transient ischemic attack; MI, myocardial infarction; CHF, congestive heart failure; ASA, aspirin.

Outcomes of interest are highlighted in bold.

Close Modal

or Create an Account

Close Modal
Close Modal